SCHEMBL1011902

SCHEMBL1011902

Nc1nc2c([N+](=O)[O-])cccc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
PDE10A Q9Y233 2/20 0.53
PDPK1 O15530 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
LMNA P02545 1/20 0.53
MAPT P10636 3/20 0.51
GAA P10253 2/20 0.49
MGAM O43451 1/20 0.49
SI P14410 1/20 0.49
MGAM2 Q2M2H8 1/20 0.49
TDP1 Q9NUW8 3/20 0.49
CYP3A4 P08684 2/20 0.49
TSHR P16473 1/20 0.46
TXNRD1 Q16881 1/20 0.46
TXNRD3 Q86VQ6 1/20 0.46
TXNRD2 Q9NNW7 1/20 0.46
NOS1 P29475 1/20 0.43
NOS2 P35228 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10426653 0.81 PDE10A (0.49) ALDH1A1PDE10ASMN1; SMN2LMNAMAPT
SCHEMBL4920165 0.81 ALDH1A1 (0.50) ALDH1A1PDE10ALMNAMAPTTDP1
SCHEMBL31122218 0.81 PDE10A (0.49) ALDH1A1PDE10ASMN1; SMN2LMNAMAPT
SCHEMBL15880740 0.80 TDP1 (0.48) ALDH1A1PDE10ASMN1; SMN2MAPTGAA
SCHEMBL10666612 0.80 PDE10A (0.47) ALDH1A1PDE10ASMN1; SMN2LMNAMAPT
SCHEMBL11210857 0.80 MEN1 (0.56) ALDH1A1PDE10ASMN1; SMN2LMNAMAPT
Potassium Ion SCHEMBL11302216 0.79 TXNRD1 (0.53) ALDH1A1PDE10ASMN1; SMN2LMNAMAPT
SCHEMBL2115313 0.78 SLC9A1 (0.44) ALDH1A1PDE10AGAAMGAMSI
SCHEMBL12479627 0.76 MEN1 (0.52) ALDH1A1PDE10ASMN1; SMN2LMNAMAPT
SCHEMBL7740046 0.76 PDE10A (0.44) ALDH1A1PDE10ALMNAMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122037615-A Photochromic yellow fluorine-containing reactive dye and preparation method and application thereof 湖北丽源科技股份有限公司 2026-05-15 CN claimed
EP-1437749-B1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR RUBYCON CORP (JP) 2013-07-17 EP claimed
US-7539006-B2 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2009-05-26 US claimed
US-20070029529-A1 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor KOMATSU AKIHIKO 2007-02-08 US claimed
US-20040245105-A1 Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2004-12-09 US claimed
EP-1437749-A1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR Rubycon Corporation (JP) 2004-07-14 EP claimed
CN-122037615-A Photochromic yellow fluorine-containing reactive dye and preparation method and application thereof 湖北丽源科技股份有限公司 2026-05-15 CN disclosed
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof Wu, Xiao Hua (US) 2019-03-05 US disclosed
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof Wu, Xiao Hua (US) 2019-03-05 US disclosed
EP-3130589-A1 HETEROCYCLIC AZA COMPOUNDS Grünenthal GmbH (DE) 2017-02-15 EP disclosed
EP-1437749-B1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR RUBYCON CORP (JP) 2013-07-17 EP disclosed
EP-1460660-B1 ELECTROLYTIC CAPACITOR AND ELECTROLYTIC SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR RUBYCON CORP (JP) 2013-04-10 EP disclosed
EP-1542692-B1 AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AMGEN INC (US) 2011-01-05 EP disclosed
US-5424439-A Process for the preparation of 2-amino-4-nitrobenzothiazole derivatives and intermediates RHONE-POULENC RORER S.A. (FR) 1995-06-13 US disclosed
US-5424439-A Process for the preparation of 2-amino-4-nitrobenzothiazole derivatives and intermediates RHONE-POULENC RORER S.A. (FR) 1995-06-13 US disclosed
CN-1023700-C Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents PFIZER (US) 1994-02-09 CN disclosed
CN-1037898-A The preparation of aromatics and Heterocyclylcarboxamderivatives derivatives antineoplastic agent PFIZER (US) 1989-12-13 CN disclosed
US-4313872-A MONDAZO AND DISAZO DYES CASSELLA AKTIENGESELLSCHAFT (DE) 1982-02-02 US disclosed
US-4118384-A DIAZOTIZATION BAYER AKTIENGESELLSCHAFT (DE) 1978-10-03 US disclosed
US-3933423-A Azoic dyeing of leather E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof MAN2A1, MAN1B1, ALG1 ALDH1A1 690/4885PDE10A 729/4885PDPK1 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.